Iperboreal Pharma S.r.l.

Address
Via L' Aquila 9

Sponsor Overview

assignment
4
sponsored trials
science
13
molecules
location_city
36
research centres
public
5
countries
person_search
41
investigators

Specializations

Nephrology and Peritoneal Dialysis

Iperboreal Pharma S.r.l. focuses on end-stage kidney disease and treatments used in peritoneal dialysis, with research centered on dialysis solutions and approaches intended to support renal replacement therapy.

  • End-stage kidney disease
  • Peritoneal dialysis
  • Glucose-sparing dialysis solutions
  • Peritoneal ultrafiltration

The sponsor’s clinical portfolio includes investigations of dialysis-related therapies for patients initiating or continuing peritoneal renal support, with attention to kidney function management and treatment tolerability.

Cardiorenal Disease and Heart Failure

The company also investigates therapies relevant to cardiorenal syndrome and congestive heart failure, reflecting an interest in conditions where cardiac and renal dysfunction overlap.

  • Congestive heart failure
  • Cardiorenal syndrome
  • Heart failure exacerbation
  • Mortality and clinical worsening

Research activity in this area includes peritoneal ultrafiltration strategies aimed at managing fluid balance and related clinical deterioration in patients with combined cardiac and renal disease.

Pediatric Nephrology

Iperboreal Pharma S.r.l. includes pediatric dialysis within its research landscape, with studies directed toward the safety of dialysis-related treatments in children.

  • Pediatric peritoneal dialysis
  • Childhood kidney disease
  • Treatment safety in children

This area highlights interest in renal therapies adapted to younger patients requiring long-term dialysis care.

Dialysis Solution Innovation

The sponsor’s trials also address the performance of novel peritoneal dialysis solutions, including formulations designed to reduce reliance on glucose and support dialysis efficiency.

  • Xylitol-based dialysis solutions
  • L-carnitine
  • Polydextrin
  • Dialysis efficacy and safety

These research interests are centered on improving solute clearance, treatment tolerability, and the clinical practicality of alternative dialysis formulations.

Sponsored Trials

Data & Insights

science
Molecule Portfolio
Compounds under investigation
4
Exclusive Molecules
out of 13 total (31% not shared with other sponsors)

This sponsor works with 13 molecules, of which 4 are not being studied by other sponsors.

hub
Site Partnerships
Collaboration with research centres
19%
Return partnership rate
7 of 36 sites collaborated multiple times

This sponsor has worked with 36 sites across their trial portfolio.

Therapeutic Focus

  • 1.
    Male Urogenital Diseases3 trials
    111 other sponsors
  • 2.
    Female Urogenital Diseases and Pregnancy Complications2 trials
    142 other sponsors
  • 3.
    Cardiovascular Diseases1 trial
    359 other sponsors

Partnered Research Centres

36 centres
location_city
assignment335
Aalborg University Hospital
Address
Moelleparkvej 4, 9000 Aalborg
Learn morearrow_forward
location_city
assignment352
Aarhus University Hospital
Address
Palle Juul-Jensens Boulevard 99, 8200 Aarhus
Learn morearrow_forward
location_city
assignment86
Area De Salud De Burgos Y Soria
Address
Avenida De Las Islas Baleares 3, 09006 Burgos
Learn morearrow_forward
location_city
assignment153
ASST Fatebenefratelli Sacco
Address
Via Giovanni Battista Grassi 74, 20157 Milan
Learn morearrow_forward
location_city
assignment392
Azienda Ospedaliera di Padova
Address
Via Nicolo' Giustiniani 2, 35128 Padua
Learn morearrow_forward
location_city
assignment94
Azienda Ospedaliera S Maria Di Terni
Address
Viale Tristano Di Joannuccio 1, 05100 Terni
Learn morearrow_forward
Page 1 of 6

Want to get in touch with this sponsor?

Send a question and we'll pass it on to Iperboreal Pharma S.r.l..

Need a custom report on this sponsor?

Competitive positioning, market entry, partnership opportunities — tell us the question.

Is something out of date?

Tell us what needs correcting and we'll update this profile.